Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Net Income towards Common Stockholders (2019 - 2025)

Historic Net Income towards Common Stockholders for Madrigal Pharmaceuticals (MDGL) over the last 13 years, with Q3 2025 value amounting to -$111.1 million.

  • Madrigal Pharmaceuticals' Net Income towards Common Stockholders fell 388.35% to -$111.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$286.0 million, marking a year-over-year increase of 4485.68%. This contributed to the annual value of -$465.9 million for FY2024, which is 2469.34% down from last year.
  • Madrigal Pharmaceuticals' Net Income towards Common Stockholders amounted to -$111.1 million in Q3 2025, which was down 388.35% from -$42.2 million recorded in Q2 2025.
  • In the past 5 years, Madrigal Pharmaceuticals' Net Income towards Common Stockholders ranged from a high of -$42.2 million in Q2 2025 and a low of -$152.0 million during Q2 2024
  • Over the past 5 years, Madrigal Pharmaceuticals' median Net Income towards Common Stockholders value was -$76.9 million (recorded in 2023), while the average stood at -$84.4 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first plummeted by 9187.08% in 2024, then surged by 7220.59% in 2025.
  • Over the past 5 years, Madrigal Pharmaceuticals' Net Income towards Common Stockholders (Quarter) stood at -$64.5 million in 2021, then crashed by 33.08% to -$85.9 million in 2022, then plummeted by 30.6% to -$112.2 million in 2023, then skyrocketed by 47.04% to -$59.4 million in 2024, then plummeted by 87.02% to -$111.1 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$111.1 million for Q3 2025, versus -$42.2 million for Q2 2025 and -$73.2 million for Q1 2025.